Bertil Lindmark

Dr. Bertil E.
Lindmark is a Venture Partner at Xgen Venture Sgr SpA, a Chairman of the Board at Aqilion AB, an Independent Director at ALK-Abello A/S and a Professor-Emeritus at University of Gothenburg.
He is on the Board of Directors at ALK-Abello A/S, Cellevate AB and Aslan Pharmaceuticals (Shanghai) Co. Ltd. Dr. Lindmark was previously employed as a Chief Medical Officer by Vicore Pharma Holding AB, a Chief Medical Officer by Galecto, Inc., a Chief Medical Officer by eTheRNA immunotherapies NV, a Chief Scientific & Medical Officer by ASLAN Pharmaceuticals Pte Ltd., an Executive Director & Executive Director-R&D by Almirall SA, a Head-Clinical Development by AstraZeneca Japan Ltd., and a Vice President by AstraZeneca Pharma India Ltd. He also served on the board at Medicon Valley Alliance FMBA. He received his doctorate degree from the University of Lund.